QTRXQuanterix Corporation

Revenue guidance slashed as commercial execution stumbles and academic spending weakens.

Quanterix (NASDAQ:QTRX) CEO Everett Cunningham said the company is repositioning its commercial organization and investing in diagnostics and clinical-trial capabilities following the integration of Akoya Biosciences, while acknowledging continued pressure in academic, government and biopharma marke

Quanterix (QTRX) is back in focus after its 10 August second quarter report, which paired higher revenue with a wider net loss, a lower full year 2026 revenue outlook, and a new Chief Commercial Officer. See our latest analysis for Quanterix. Quanterix’s share price has been under pressure for some time, with the year to date share price return down 59.18% and the 1 year total shareholder return down 44.85%. The stock briefly rebounded with an 8.47% 1 day share price gain after the 10 August...

Quanterix Corp (QTRX) lowers full-year 2026 revenue guidance to $142-$148 million as it navigates broad-based market headwinds and pushes cash flow break-even to 2027.

Quanterix reported 34% second-quarter revenue growth and lower adjusted cash usage, but weaker-than-expected commercial performance prompted a substantial guidance reduction and pushed expected cash-flow break-even into 2027. Key Investor TakeawaysQuanterix (NASDAQ:QTRX) reported Q2 2026 revenue of $32.

Quanterix (NASDAQ:QTRX) reported second-quarter 2026 revenue of $32.9 million and lowered its full-year outlook after management cited broad-based market softness and commercial execution challenges. The company said revenue came in about $3 million, or 9%, below the guidance it provided in May. Re

Need a quote from a Motley Fool analyst? Joshua Young: Thank you, Preyila, and good afternoon, everybody. With me on today's call are Everett Cunningham, Quanterix' President and CEO; and Vandana Sriram, Quanterix' Chief Financial Officer.

Moby summary of Quanterix Corporation's Q1 2026 earnings call